Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian in healthy Japanese participants
NCT03224260Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of milvexian in thrombosis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Occurrence of Death, Incidence of Serious Adverse Events and 5 more. Started Jun 2017; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03224260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224260.